359 related articles for article (PubMed ID: 28786768)
1. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.
Fasano S; Margiotta DP; Navarini L; Pierro L; Pantano I; Riccardi A; Afeltra A; Valentini G
Lupus; 2017 Dec; 26(14):1463-1472. PubMed ID: 28786768
[TBL] [Abstract][Full Text] [Related]
2. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
3. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
Fasano S; Margiotta DPE; Pierro L; Navarini L; Riccardi A; Afeltra A; Valentini G
Clin Rheumatol; 2019 Feb; 38(2):457-463. PubMed ID: 30194649
[TBL] [Abstract][Full Text] [Related]
4. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study.
Iudici M; Fasano S; Gabriele Falcone L; Pantano I; La Montagna G; Migliaresi S; Valentini G
Rheumatology (Oxford); 2016 Sep; 55(9):1623-30. PubMed ID: 27247433
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
6. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.
Arnaud L; Mathian A; Devilliers H; Ruffatti A; Tektonidou M; Forastiero R; Pengo V; Lambert M; Lefevre G; Martinez-Zamora MA; Balasch J; Wahl D; Amoura Z
Autoimmun Rev; 2015 Mar; 14(3):192-200. PubMed ID: 25461472
[TBL] [Abstract][Full Text] [Related]
7. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Petri M
Curr Rheumatol Rep; 2011 Feb; 13(1):77-80. PubMed ID: 20978875
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies.
Masson W; Rossi E; Mora-Crespo LM; Cornejo-Peña G; Pessio C; Gago M; Alvarado RN; Scolnik M
Clin Rheumatol; 2020 Feb; 39(2):455-462. PubMed ID: 31802350
[TBL] [Abstract][Full Text] [Related]
9. Statins for prevention of cardiovascular disease in systemic lupus erythematosus.
Yousef Yengej FA; Limper M; Leavis HL
Neth J Med; 2017 Apr; 75(3):99-105. PubMed ID: 28469051
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state.
McVeigh ED; Batool A; Stromberg A; Abdel-Latif A; Kazzaz NM
Lupus Sci Med; 2021 May; 8(1):. PubMed ID: 33952624
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Demir S; Artim-Esen B; Şahinkaya Y; Pehlivan Ö; Alpay-Kanıtez N; Omma A; Erer B; Kamalı S; Gül A; Aral O; Öcal L; İnanç M
Lupus; 2016 Feb; 25(2):177-84. PubMed ID: 26354963
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Impact of Statins on the Lipid Profile and Cardiovascular Risk in Patients With Systemic Lupus Erythematosus: Systematic Review of the Literature and a Meta-analysis.
Sánchez P; Toro-Trujillo E; Muñoz-Velandia OM; García AA; Fernández-Ávila DG
Reumatol Clin (Engl Ed); 2019; 15(6):e86-e91. PubMed ID: 29428197
[TBL] [Abstract][Full Text] [Related]
13. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Haugaard JH; Dreyer L; Ottosen MB; Gislason G; Kofoed K; Egeberg A
J Am Acad Dermatol; 2021 Apr; 84(4):930-937. PubMed ID: 33321159
[TBL] [Abstract][Full Text] [Related]
14. [Assessing the cardiovascular risk in patients with systemic lupus erythematosus].
Arnaud L; Mathian A; Bruckert E; Amoura Z
Rev Med Interne; 2014 Nov; 35(11):723-9. PubMed ID: 25234464
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review.
Benvenuti F; Gatto M; Larosa M; Iaccarino L; Punzi L; Doria A
Expert Opin Drug Saf; 2015; 14(9):1373-85. PubMed ID: 26212119
[TBL] [Abstract][Full Text] [Related]
16. [Narcolepsy associated with systemic lupus erythematosus].
Haddad F; Anouti S; Maalouly G; Koussa S
Rev Med Interne; 2011 Nov; 32(11):e114-5. PubMed ID: 21145142
[TBL] [Abstract][Full Text] [Related]
17. Risks and benefits of statins in lupus erythematosus.
Noël B
Arch Intern Med; 2004 Jan; 164(1):107-8. PubMed ID: 14718334
[No Abstract] [Full Text] [Related]
18. Cardiovascular Outcomes in Systemic Lupus Erythematosus.
Sairam S; Sureen A; Gutierrez J; Dang TQ; Mishra K
Curr Cardiol Rep; 2022 Feb; 24(2):75-83. PubMed ID: 35028818
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins.
Ballarano CA; Frishman WH
Cardiol Rev; 2021 Nov-Dec 01; 29(6):323-327. PubMed ID: 34609986
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review.
Andrades C; Fuego C; Manrique-Arija S; Fernández-Nebro A
Lupus; 2017 Nov; 26(13):1407-1419. PubMed ID: 28457197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
